lapatinib has been researched along with Adverse Drug Event in 14 studies
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 0 (0.00) | 18.2507 |
| 2000's | 2 (14.29) | 29.6817 |
| 2010's | 10 (71.43) | 24.3611 |
| 2020's | 2 (14.29) | 2.80 |
| Authors | Studies |
|---|---|
| Chen, M; Fang, H; Liu, Z; Shi, Q; Tong, W; Vijay, V | 1 |
| Ding, D; Fang, H; Kelly, R; Liu, Z; Shi, Q; Tong, W | 1 |
| Jackson, DB; Kim, S; Lahu, G; Lesko, LJ; Soldatos, TG; Trame, MN; Vakilynejad, M | 1 |
| Ito, Y; Kondo, M; Koseki, T; Tanaka, J; Yamada, S | 1 |
| Ameels, H; Baselga, J; Berghorn, M; Borrego, MR; Bozovic-Spasojevic, I; Bradbury, I; Campbell, C; Chen, DR; de Azambuja, E; Di Cosimo, S; Ewer, M; Fumagalli, D; Harbeck, N; Huober, J; Im, YH; Izquierdo, M; Lambertini, M; Maetens, M; Piccart, M; Ponde, N; Pusztai, L; Rodeheffer, R; Suter, T; Zardavas, D | 1 |
| Hunt, CM; Spraggs, CF; Xu, CF | 1 |
| Brewster, AM; Esteva, FJ; Florance, AM; Franco, SX; Hagan, MK; Perez, A; Somer, RA; Stein, S; Turner, S; Williams, W | 1 |
| Barroso-Sousa, R; de Melo Gagliato, D; Mano, MS; Santana, IA; Testa, L | 1 |
| He, Z; Li, G; Li, J; Lin, Y; Qiu, K; Wu, J; Zhu, J | 1 |
| Gao, B; Guo, L; Hao, S; Hu, C; Jiang, Y; Luo, D; Tian, W; Yan, J; Zhang, G; Zhang, S; Zhang, X; Zhao, J | 1 |
| Balint, C; Bekaii-Saab, T; Campbell, A; Chen, H; Culler, K; Dai, Z; Dancey, J; Eng, C; Grever, M; Heerema, N; Lee, RM; Markowitz, J; O'Neil, B; Papp, A; Prescott, N; Sadee, W; Villalona-Calero, M; Wei, L; Zalupski, M | 1 |
| Bachelot, T; Campone, M; Cropet, C; Curé, H; Dalenc, F; Diéras, V; Domont, J; Ferrero, JM; Gonçalves, A; Gutierrez, M; Jimenez, M; Labbe-Devilliers, C; Le Rhun, E; Leheurteur, M; Pierga, JY; Romieu, G | 1 |
| Aktan, G; Boyle, F; Buzdar, AU; Chavarri-Guerra, Y; Ejlertsen, B; Finkelstein, DM; Fumoleau, P; Goss, PE; Gradishar, W; Kaufmann, M; Lindquist, D; Martin, M; Moy, B; O'Shaughnessy, J; Piccart-Gebhart, M; Pritchard, KI; Rappold, E; Smith, IE; Williams, LS | 1 |
| Dipetrillo, T; Evans, D; Gutman, N; Joseph, P; Kennedy, T; McNulty, B; Millis, R; Miner, T; Plette, A; Resnick, M; Safran, H; Sears, D | 1 |
4 review(s) available for lapatinib and Adverse Drug Event
| Article | Year |
|---|---|
Genetic characterization to improve interpretation and clinical management of hepatotoxicity caused by tyrosine kinase inhibitors.
Topics: Biomarkers, Pharmacological; Chemical and Drug Induced Liver Injury; Drug-Related Side Effects and Adverse Reactions; Gilbert Disease; Glucuronosyltransferase; Humans; Indazoles; Lapatinib; Protein Kinase Inhibitors; Pyrimidines; Quinazolines; Sulfonamides | 2013 |
Biological therapies in breast cancer: common toxicities and management strategies.
Topics: Ado-Trastuzumab Emtansine; Angiogenesis Inhibitors; Antibodies, Monoclonal, Humanized; Antineoplastic Agents; Bevacizumab; Biological Therapy; Breast Neoplasms; Drug-Related Side Effects and Adverse Reactions; Everolimus; Humans; Immunosuppressive Agents; Lapatinib; Maytansine; Quinazolines; Sirolimus; Trastuzumab | 2013 |
Meta-analysis of randomized controlled trials for the incidence and risk of treatment-related mortality in patients with breast cancer treated with HER2 blockade.
Topics: Adult; Antibodies, Monoclonal, Humanized; Antineoplastic Agents; Breast Neoplasms; Drug-Related Side Effects and Adverse Reactions; Female; Humans; Incidence; Lapatinib; Middle Aged; Quinazolines; Randomized Controlled Trials as Topic; Receptor, ErbB-2; Risk Factors; Trastuzumab | 2015 |
Does dual HER-2 blockade treatment increase the risk of severe toxicities of special interests in breast cancer patients: A meta-analysis of randomized controlled trials.
Topics: Antibodies, Monoclonal, Humanized; Antineoplastic Agents; Antineoplastic Combined Chemotherapy Protocols; Breast Neoplasms; Diarrhea; Drug-Related Side Effects and Adverse Reactions; Exanthema; Female; Humans; Lapatinib; Quinazolines; Randomized Controlled Trials as Topic; Receptor, ErbB-2; Risk Factors; Trastuzumab; Treatment Outcome; Withholding Treatment | 2017 |
6 trial(s) available for lapatinib and Adverse Drug Event
| Article | Year |
|---|---|
Cardiac biomarkers for early detection and prediction of trastuzumab and/or lapatinib-induced cardiotoxicity in patients with HER2-positive early-stage breast cancer: a NeoALTTO sub-study (BIG 1-06).
Topics: Aged; Biomarkers; Breast Neoplasms; Cardiotoxicity; Cardiovascular Abnormalities; Drug-Related Side Effects and Adverse Reactions; Female; Humans; Lapatinib; Middle Aged; Natriuretic Peptide, Brain; Neoplasm Staging; Paclitaxel; Receptor, ErbB-2; Trastuzumab; Troponin T | 2018 |
An open-label safety study of lapatinib plus trastuzumab plus paclitaxel in first-line HER2-positive metastatic breast cancer.
Topics: Adult; Antibodies, Monoclonal, Humanized; Antineoplastic Combined Chemotherapy Protocols; Breast Neoplasms; Drug Administration Schedule; Drug-Related Side Effects and Adverse Reactions; Female; Humans; Lapatinib; Middle Aged; Neoplasm Metastasis; Paclitaxel; Quinazolines; Receptor, ErbB-2; Trastuzumab | 2013 |
A multi-institutional phase II study of the efficacy and tolerability of lapatinib in patients with advanced hepatocellular carcinomas.
Topics: Adult; Aged; Aged, 80 and over; Carcinoma, Hepatocellular; Disease Progression; Dose-Response Relationship, Drug; Drug-Related Side Effects and Adverse Reactions; Female; Humans; Lapatinib; Liver Neoplasms; Male; Maximum Tolerated Dose; Middle Aged; Predictive Value of Tests; Quinazolines; Survival Rate | 2009 |
Lapatinib plus capecitabine in patients with previously untreated brain metastases from HER2-positive metastatic breast cancer (LANDSCAPE): a single-group phase 2 study.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Brain Neoplasms; Breast Neoplasms; Capecitabine; Central Nervous System; Deoxycytidine; Drug-Related Side Effects and Adverse Reactions; Endpoint Determination; Female; Fluorouracil; Humans; Lapatinib; Middle Aged; Neoplasm Staging; Quinazolines; Receptor, ErbB-2 | 2013 |
Adjuvant lapatinib for women with early-stage HER2-positive breast cancer: a randomised, controlled, phase 3 trial.
Topics: Adult; Aged; Aged, 80 and over; Antibodies, Monoclonal, Humanized; Breast Neoplasms; Chemotherapy, Adjuvant; Disease-Free Survival; Drug-Related Side Effects and Adverse Reactions; Female; Humans; Lapatinib; Lymph Nodes; Middle Aged; Neoplasm Staging; Quinazolines; Receptor, ErbB-2; Trastuzumab | 2013 |
Lapatinib/gemcitabine and lapatinib/gemcitabine/oxaliplatin: a phase I study for advanced pancreaticobiliary cancer.
Topics: Adenocarcinoma; Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Bile Duct Neoplasms; Deoxycytidine; Dose-Response Relationship, Drug; Drug-Related Side Effects and Adverse Reactions; Female; Gemcitabine; Humans; Lapatinib; Male; Middle Aged; Organoplatinum Compounds; Pancreatic Neoplasms; Protein Kinase Inhibitors; Pyridines; Quinazolines; Survival Analysis | 2008 |
4 other study(ies) available for lapatinib and Adverse Drug Event
| Article | Year |
|---|---|
FDA-approved drug labeling for the study of drug-induced liver injury.
Topics: Animals; Benchmarking; Biomarkers, Pharmacological; Chemical and Drug Induced Liver Injury; Drug Design; Drug Labeling; Drug-Related Side Effects and Adverse Reactions; Humans; Pharmaceutical Preparations; Reproducibility of Results; United States; United States Food and Drug Administration | 2011 |
Translating clinical findings into knowledge in drug safety evaluation--drug induced liver injury prediction system (DILIps).
Topics: Animals; Anti-Infective Agents; Anti-Inflammatory Agents; Chemical and Drug Induced Liver Injury; Databases, Factual; Drug-Related Side Effects and Adverse Reactions; Humans; Liver; Models, Biological; Predictive Value of Tests | 2011 |
A case study of a patient-centered reverse translational systems-based approach to understand adverse event profiles in drug development.
Topics: Cardiotoxicity; Doxorubicin; Drug Development; Drug-Related Side Effects and Adverse Reactions; Humans; Lapatinib; Paroxetine; Patient-Centered Care; Tamoxifen; Trastuzumab | 2022 |
Analyses of Ocular Adverse Reactions Associated With Anticancer Drugs Based on the Japanese Pharmacovigilance Database.
Topics: Adverse Drug Reaction Reporting Systems; Antineoplastic Agents; Databases, Factual; Drug-Related Side Effects and Adverse Reactions; Humans; Imatinib Mesylate; Japan; Lapatinib; Pharmacovigilance; Tamoxifen | 2022 |